Five Covid Vaccines for Children: The Ministry of Health and Family Welfare notified Parliament on Friday that five Covid-19 vaccinations for children ages 2 and older will soon be available. According to Dr Bharati Pravin Pawar, a Minister of state in the Union Health Ministry, a clinical study of five Covid-19 vaccinations in children and adolescents has been approved by an Apex medical body of Government of India. Though there are five covid vaccines approved officially, as on 3rd January 2022, children can take vaccines and only Covaxin is available for this purpose.
Table of Contents
The Five Covid Vaccines for Children
Biological E’s RBD; Bharat Biotech’s Covaxin; ZyCoV-D, Serum Institute’s Covax; and Johnson & Johnson’s Ad 26COV.2S vaccine are the five vaccines that are under consideration
Covid Vaccines for Children – ZyCoV-D
ZyCoV-D (recombinant DNA) has been tested in the 12 and older age group in a Phase III trial undertaken by Cadila Healthcare. Restrictions on its usage in children 12 and older during an emergency necessitated the vaccine’s approval.
Zydus Cadila’s COVID-19 vaccine ZyCoV-D will first be deployed in seven states, according to Rajesh Bhushan, the Union Health Secretary (Uttar Pradesh, West Bengal, Punjab, Maharashtra, Tamil Nadu, Jharkhand and Bihar).
Zydus Cadila said on 8th November that the Indian government has ordered one million doses of ZyCoV-D at a cost of 265 per dosage.
India will receive one million doses of ZyCoV-D, the world’s first Plasmodium DNA Vaccine, at a cost of INR 265 per dosage and the needle-free applicator at a cost of INR 93 per dose, according to a Zydus Cadila regulatory filing.
The three ZyCoV-D dosages are to be taken 28 days apart. The Indian medicines regulator granted emergency use authorization (EUA) for the vaccination on August 20.
Covid Vaccines for Children – Covaxin
A clinical trial of Covaxin, on the other hand, is being conducted by Bharat biotech on healthy volunteers ages 2 to 18. Pawar informed Parliament today that the company has presented interim safety and immunogenicity data.
Covid-19 Vaccines for Children – COVOVAX
There are 920 patients in the Phase II/III clinical study of nanoparticle vaccine (Liquid) COVOVAX being conducted by the Serum Institute of India.
Covid Vaccines for Children – RBD
There are now 624 participants ages 5 to 18 participating in Biological E Ltd.’s Phase II/III clinical study using RBD for the SARS-CoV-2 gene.
Covid Vaccines for Children – Ad 26COV.2S (Johnson & Johnson)
Ad 26COV.2S vaccine is also being tested in children between the ages of 12 and 17 in a clinical study by Johnson & Johnson Pvt. Ltd.
Latest Covid News: